8-K: Zomedica Q3 Revenue Jumps 16% to $8.1M, Gross Margin at 67%

Zomedica Corp. reported its highest-ever quarterly revenue of $8.1 million, a 16% increase year-over-year, driven by strong diagnostic and new development services growth, alongside a 67% gross margin and $54.4 million in liquidity.

Summary

• Revenue for the third quarter of 2025 increased by 16% to $8.1 million, marking the highest quarterly revenue ever and the 19th consecutive quarter of year-over-year growth.
• Gross margin for the quarter was 67%.
• Total operating expenses decreased by $0.5 million, or 4%, to $12.0 million compared to $12.5 million in Q3 2024.
• Net loss for the quarter was $6.1 million, a 9% reduction from $6.7 million in Q3 2024.
• Non-GAAP EBITDA loss improved by 19% to $3.9 million, and Adjusted Non-GAAP EBITDA loss improved by 14% to $3.7 million.
• The Diagnostics segment revenue grew by 51% to $0.7 million, primarily due to accelerating adoption of the TRUFORMA platform and an expanded assay menu.
• A new Development Services segment generated $0.7 million in revenue from work in the human health sector.
• Consumable revenues increased by 14% to $5.4 million, driven by TRUFORMA products and PulseVet trodes.
• International sales grew by 16% compared to Q3 2024, supported by new distributor partnerships in the UK, Netherlands, and Canada.
• Zomedica held $54.4 million in cash, cash equivalents, and available-for-sale securities as of September 30, 2025.
• The company had 979,949,668 common shares issued and outstanding as of September 30, 2025.

Sentiment

Score: 8

Explanation: The filing presents strong financial performance with record revenue, improved profitability metrics, high gross margins, and successful strategic initiatives like the new Development Services segment and international expansion. The company also maintains a healthy liquidity position and expresses a clear line of sight to cash flow breakeven and profitability. While still operating at a loss, the positive trends and strategic execution warrant a high sentiment score.

Positives

• Achieved highest quarterly revenue ever at $8.1 million, representing a 16% year-over-year increase.
• Recorded 19th straight quarter of year-over-year revenue growth, demonstrating consistent business resilience.
• Maintained a strong gross margin of 67%.
• Reduced total operating expenses by 4% ($0.5 million) for the quarter and $2.5 million year-to-date through cost-reduction initiatives.
• Net loss decreased by 9% to $6.1 million.
• Non-GAAP EBITDA loss and Adjusted Non-GAAP EBITDA loss both improved significantly by 19% and 14% respectively.
• Diagnostics segment revenue surged by 51%, driven by strong adoption of the TRUFORMA platform.
• Successfully launched a new Development Services segment, generating $0.7 million in its first quarter from the human health space.
• Consumable revenues grew by 14%, reinforcing a recurring revenue model.
• International sales increased by 16%, supported by new strategic distribution agreements and strengthened partnerships.
• Expanded the TRUFORMA diagnostic platform with new feline testing capabilities for cobalamin and folate.
• Secured four additional U.S. patents, extending TRUFORMA assay capabilities and protecting the TRUVIEW microscope.
• Maintained a strong balance sheet with $54.4 million in liquidity, providing capital to support growth and strategic initiatives.

Negatives

• Despite revenue growth and expense reductions, the company still reported a net loss of $6.1 million and an Adjusted Non-GAAP EBITDA loss of $3.7 million for the quarter.
• Selling and marketing expenses increased by 12% to $4.3 million, primarily due to increased headcount and commissions, which could impact future profitability if not offset by higher sales efficiency.

Risks

• Uncertainty as to whether the human health company will enter into a written agreement for development and engineering services, contract manufacturing, and/or licensing of intellectual property.
• Uncertainty as to whether the new Development Services business segment will continue to generate revenue.
• The outcome of clinical studies may not be favorable.
• The application of generally accepted accounting principles is highly complex and involves many subjective assumptions, estimates, and judgments.
• Uncertainty as to whether strategies and business plans will yield the expected benefits.
• Uncertainty as to the timing and results of development work and verification and validation studies.
• Uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage growth.
• Uncertainty as to the ability to realize the anticipated growth opportunities from acquisitions.
• Uncertainty as to the ability to supply products in response to customer demand.
• Supply chain risks associated with tariff changes.
• Uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital.
• The ability to identify, develop, and achieve commercial success for new products and technologies.
• Veterinary acceptance of products and purchase of consumables following adoption of capital equipment.
• Competition from related products.
• The level of expenditures necessary to maintain and improve the quality of products and services.
• Changes in technology and changes in laws and regulations.
• The ability to secure and maintain strategic relationships.
• Performance by strategic partners of their obligations under commercial agreements, including product manufacturing obligations.
• Risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of products, the use of products, and intellectual property protection.

Future Outlook

Management is optimistic about continuing to generate increasing revenue from the new Development Services segment, which is expected to provide operating leverage. The company plans to introduce further enhancements to its VETGuardian system and launch its TRUVIEW AI platform in the coming quarter. Zomedica believes it has a clear line of sight to cash flow breakeven and profitability, supported by its strong balance sheet and strategy to accelerate global adoption of its product portfolio.

Management Comments

• "Delivering 16% growth and achieving record year-over-year revenue for the 19th straight quarter demonstrates the consistency and resilience of our business. Crossing $8 million in quarterly sales for the first time is a proud moment for our company and a clear indicator that our long-term strategy is working."
• "Fueled by robust demand for our PulseVet and Assisi therapeutic device products, continued accelerated growth and adoption of our diagnostic products, including our expanding TRUFORMA platform, and the successful introduction of our new Development Services revenue stream, we delivered the strongest quarter in company history."
• "As we continue to identify ways to leverage our infrastructure and intellectual property assets, the new Development Services business segment captures revenue we generate from providing development and engineering services along with contract manufacturing and licensing of our intellectual property."
• "We are optimistic about our ability to continue to generate increasing revenue from this new segment, providing planned operating leverage."
• "Ongoing portfolio expansion and optimization of our commercial organization continue to drive strong performance, as evidenced by 51% growth in our Diagnostic segment and 14% growth in total Consumable sales year-over-year. This performance reinforces our recurring revenue model and positions us for sustained long-term growth."
• "We remain committed to continuously advancing our products to meet the evolving needs of veterinarians and their patients."
• "Gross margin, a key component of reaching profitability, came in at 67%. Our disciplined execution of cost-reduction initiatives continues to pay off, resulting in a $0.5 million reduction in OPEX for the quarter ended September 30, 2025 and $2.5 million year-to-date."
• "Building on the momentum we've achieved through the third quarter and supported by the strength of our balance sheet, we believe we are well positioned to execute on our strategy to accelerate the global adoption of our innovative portfolio, providing us with a clear line of sight to cash flow breakeven and profitability."

Industry Context

Zomedica operates in the growing animal health market, specifically focusing on point-of-care diagnostic and therapeutic products for equine and companion animals. The reported growth in diagnostics (51%) and consumables (14%) aligns with broader industry trends favoring advanced veterinary care and recurring revenue models. The introduction of a Development Services segment, leveraging intellectual property in the human health space, indicates a strategic diversification that could provide additional revenue streams and operating leverage, potentially differentiating Zomedica from pure-play animal health competitors. International expansion efforts, particularly in advanced veterinary markets like the UK, reflect a common strategy among animal health companies to tap into global demand.

Comparison to Industry Standards

• Zomedica's 16% year-over-year revenue growth is strong, especially considering the competitive landscape in animal health. For context, larger players like Zoetis (ZTS) and Elanco Animal Health (ELAN) typically report revenue growth in the mid-to-high single digits, making Zomedica's growth rate competitive for a smaller, growing company.
• The 67% gross margin is robust and generally higher than many diversified animal health companies, which often range from 50-65%. This indicates strong product profitability, comparable to specialized diagnostic or therapeutic device manufacturers.
• The 51% growth in the Diagnostics segment, driven by the TRUFORMA platform, is particularly noteworthy. This outpaces the general growth rate of the global veterinary diagnostics market, which is projected to grow at a CAGR of around 8-10% in the coming years, suggesting strong market penetration and adoption for Zomedica's offerings.
• The introduction of a Development Services segment with $0.7 million in revenue from the human health space is an innovative move. While not directly comparable to standard animal health metrics, it demonstrates a strategic effort to monetize intellectual property and infrastructure beyond the core market, a strategy sometimes seen in larger diversified life sciences companies.
• The company's liquidity of $54.4 million provides a solid financial cushion for continued investment in R&D, commercial expansion, and potential acquisitions, which is a healthy position for a company aiming for cash flow breakeven and profitability.

Stakeholder Impact

• Shareholders: Positive impact due to record revenue growth, improved profitability metrics, strong gross margins, and a healthy balance sheet, which could lead to increased shareholder value over time. The clear line of sight to cash flow breakeven and profitability is a significant positive.
• Employees: Positive impact due to increased headcount in the sales department, indicating growth and potential for career development. Cost-reduction initiatives are being managed to drive efficiency without explicitly mentioning negative impacts on employees.
• Customers (Veterinarians and Pet Owners): Positive impact through expanded product offerings (e.g., TRUFORMA feline testing, VETGuardian enhancements, TRUVIEW AI) and broader access to products via new distribution partnerships, enhancing the quality of care for animals.
• Suppliers: Potential positive impact from increased demand for products and consumables, leading to more business.
• Creditors: Positive impact from the company's strong liquidity position ($54.4 million) and progress towards profitability, reducing credit risk.

Next Steps

• Introduce further enhancements to the VETGuardian system in the coming quarter.
• Launch the TRUVIEW AI platform in the coming quarter.
• Host the 'Fourth Friday at Four Webinar' (adjusted to November 21, 2025) to review and discuss third-quarter financial performance.
• Continue to execute on the strategy to accelerate global adoption of the innovative product portfolio.
• Continue efforts to achieve cash flow breakeven and profitability.

Key Dates

Recommendation

The filing demonstrates exceptional operational execution and financial momentum. Zomedica achieved record quarterly revenue, sustained a high gross margin, significantly reduced its net and EBITDA losses, and successfully launched a new revenue stream. The 51% growth in the Diagnostics segment and 14% growth in consumables highlight strong product adoption and a robust recurring revenue model. With $54.4 million in liquidity and a stated 'clear line of sight to cash flow breakeven and profitability,' the company is well-capitalized to continue its growth trajectory and strategic initiatives. The consistent year-over-year growth for 19 consecutive quarters underscores the business's resilience and the effectiveness of its long-term strategy. These factors collectively suggest a strong investment opportunity with significant upside potential.

Keywords

Animal Health, Veterinary Diagnostics, Veterinary Therapeutics, TRUFORMA, PulseVet, Assisi Loop, VETGuardian, TRUVIEW, Financial Results, Q3 2025, Revenue Growth, Gross Margin, SEC Filing, Zomedica